

Haoran Zhang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10074468/publications.pdf>

Version: 2024-02-01

30
papers

347
citations

1040056

9
h-index

839539

18
g-index

34
all docs

34
docs citations

34
times ranked

575
citing authors

#	ARTICLE	IF	CITATIONS
1	Integrated Molecular Characterization of Fumarate Hydratase-deficient Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 1734-1743.	7.0	54
2	Differential expressions of PD-1, PD-L1 and PD-L2 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 360.	2.6	52
3	Integrated exome and RNA sequencing of TFE3-translocation renal cell carcinoma. <i>Nature Communications</i> , 2021, 12, 5262.	12.8	40
4	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: a systematic review and meta-analysis. <i>World Journal of Surgical Oncology</i> , 2020, 18, 42.	1.9	32
5	AKR1C3 expression in primary lesion rebiopsy at the time of metastatic castration-resistant prostate cancer is strongly associated with poor efficacy of abiraterone as a first-line therapy. <i>Prostate</i> , 2019, 79, 1553-1562.	2.3	22
6	Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma. <i>BMC Cancer</i> , 2019, 19, 49.	2.6	21
7	Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion >5%: a propensity score matching analysis from SEER database. <i>Scientific Reports</i> , 2019, 9, 17985.	3.3	19
8	Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate. <i>BJU International</i> , 2022, 129, 345-355.	2.5	18
9	The Adiponectin-AdipoR1 Axis Mediates Tumor Progression and Tyrosine Kinase Inhibitor Resistance in Metastatic Renal Cell Carcinoma. <i>Neoplasia</i> , 2019, 21, 921-931.	5.3	16
10	Dynamic multidisciplinary team discussions can improve the prognosis of metastatic castration-resistant prostate cancer patients. <i>Prostate</i> , 2021, 81, 721-727.	2.3	15
11	Comparison of the prognosis of primary and progressive muscle-invasive bladder cancer after radical cystectomy: A systematic review and meta-analysis. <i>International Journal of Surgery</i> , 2018, 52, 214-220.	2.7	9
12	The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer. <i>Prostate</i> , 2021, 81, 1191-1201.	2.3	9
13	Exosomal TUBB3 mRNA expression of metastatic castration-resistant prostate cancer patients: Association with patient outcome under abiraterone. <i>Cancer Medicine</i> , 2021, 10, 6282-6290.	2.8	8
14	Does ductal adenocarcinoma of the prostate (DA) have any prognostic impact on patients with de novo metastatic prostate cancer?. <i>Prostate</i> , 2019, 79, 1673-1682.	2.3	7
15	Survival Outcomes of Radical Prostatectomy + Extended Pelvic Lymph Node Dissection and Radiotherapy in Prostate Cancer Patients With a Risk of Lymph Node Invasion Over 5%: A Population-Based Analysis. <i>Frontiers in Oncology</i> , 2020, 10, 607576.	2.8	4
16	<p>The Prognostic Value of Body Fat Components in Metastasis Renal Cell Carcinoma Patients Treated with TKIs</p>. <i>Cancer Management and Research</i> , 2020, Volume 12, 891-903.	1.9	4
17	Clinical outcomes of second-line treatment following first-line VEGFR-TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti-PD-1 antibody. <i>Cancer Communications</i> , 2021, 41, 1071-1074.	9.2	4
18	Efficacy and Safety of Individualized Schedule of Sunitinib by Drug Monitoring in Patients with Metastatic Renal Cell Carcinoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 6833-6845.	1.9	4

#	ARTICLE	IF	CITATIONS
19	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. American Journal of Translational Research (discontinued), 2020, 12, 5416-5432.	0.0	4
20	The Impact of Renal Impairment on Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With Tyrosine Kinase Inhibitors. Cancer Control, 2020, 27, 107327482097714.	1.8	2
21	The influence of dynamic changes in lipid metabolism on survival outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Japanese Journal of Clinical Oncology, 2020, 50, 1454-1463.	1.3	2
22	The effect of AKR1C3 on the switch from prednisone to dexamethasone in metastatic castration-resistant prostate cancer patients receiving abiraterone.. Journal of Clinical Oncology, 2020, 38, 133-133.	1.6	1
23	The prognostic value of body fat components in metastasis renal cell carcinoma patients treated with TKIs.. Journal of Clinical Oncology, 2020, 38, 668-668.	1.6	0
24	High-exosomal AKR1C3 mRNA expression as a marker of poor efficacy of abiraterone in metastatic PCa patients.. Journal of Clinical Oncology, 2020, 38, 196-196.	1.6	0
25	Occurrence of tyrosine kinase inhibitors-induced renal impairment and its predictive value for the prognosis of patients with metastatic renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 693-693.	1.6	0
26	Exosomal TUBB3 mRNA expression level to predict prognosis for abiraterone treatment in metastatic prostate patients.. Journal of Clinical Oncology, 2020, 38, 244-244.	1.6	0
27	The efficacy and safety of radical prostatectomy and radiotherapy in high-risk prostate cancer: A systematic review and meta-analysis.. Journal of Clinical Oncology, 2020, 38, 369-369.	1.6	0
28	Genomic landscape and immune microenvironment features of FH-deficient renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 717-717.	1.6	0
29	Distinctive landscape of genetic mutation in patients with intraductal carcinoma of the prostate (IDC-P).. Journal of Clinical Oncology, 2020, 38, 192-192.	1.6	0
30	Efficacy of second-line ICIs combined with TKIs among patients with metastatic renal cell carcinoma: a real-world study. Immunotherapy, 2022, 14, 309-320.	2.0	0